Anti-CLTA polyclonal antibody

Cytotoxic T lymphocyte Antigen 4 (CTLA-4), similar to co-stimulatory molecule CD28, plays an important role in down regulation of T cell activation..CLTA-4 binds to B7 with much greater affinity as compared to CD28, thus limiting the enhanced activation of T cells and preventing autoimmune diseases. CTLA-4 gene has an important variation rs231775 which interferes with the functioning of CTLA-4 causing uncontrolled activation of T cells. rs231775 may prone individuals to development of rheumatoid arthritis (RA), a severe autoimmune disease. This study aims to find the possible role of rs231775 polymorphism and the risk factors smoking, hypertension and diabetes in conferring susceptibility to RA in Pakistani population. Allele specific PCR based strategy was used to amplify rs231775 in samples of 100 RA patients and 100 age and sex matched healthy individuals. GG genotype of rs231775 polymorphism was found to increase the risk of RA development by 3.0186 times (OR 3.0186; 95% CI 1.6774-5.4322). Smoking increased the risk of RA development by 3.1672 times (OR or 3.1672; 95% CI 1.77665.6462). Diabetes was found to increase the risk of RA development by 2.172 times (OR 2.172; 95% CI 1.18973.9669). Hypertension also increased the risk of RA development by 2.280 times (OR 2.280; 95% CI 1.2676-4.1021). It can be concluded that smoking, diabetes, hypertension and rs231775 play an important role in development of RA in Pakistani population.

Patients with triple-negative breast cancer (TNBC) have a poor prognosis, partly because of the absence of targeted therapies. Recognition of the key role of immune responses against cancer has allowed the advent of immunotherapy, focused on the inhibition of negative immune checkpoints, such as CTLA-4. CTLA-4 is also expressed in some cancer cells, but its activity in tumor cells is not completely understood. Thus, the aim of the present work was to determine the biological landscape and functions of CTLA-4 expressed in TNBC cells through preclinical andin silicoanalysis. Exploration of CTLA-4 by immunohistochemistry in 50 TNBC tumors revealed membrane and cytoplasmic expression at different intensities. Preclinical experiments, using TNBC cell lines, showed that stimulation of CTLA-4 with CD80 enhances activation of the ERK1/2 signaling pathway, while CTLA-4 blockade by Ipilimumab induces the activation of AKT and reduces cell proliferationin vitro. We then developed an analytic pipeline to define the effects of CTLA-4 in available public data that allowed us to identify four distinct tumor clusters associated with CTLA-4 activation, which are characterized by enrichment of distinctive pathways associated with cell adhesion, MAPK signaling, TGF-ss, VEGF, TNF-alpha, drug metabolism, ion and amino acid transport, and KRAS signaling, among others. In addition, blockade of CTLA-4 induced increased secretion of IL-2 by tumor cells, suggesting that the receptor regulates cellular functions that may impact the immune microenvironment. This is relevant because a deep characterization of immune infiltrate, conducted using public data to estimate the abundancies of immune-cell types, showed that CTLA-4-activated-like tumors present a conditional immune state similar to an escape phenotype exploited by cancer cells. Finally, by interrogating transcriptional predictors of immunotherapy response, we defined that CTLA-4 activation correlates with high immune scores related to good clinical predicted responses to anti-CTLA-4 therapy. This work sheds new light on the roles of activated CLTA-4 in the tumor compartment and suggests an important interplay between tumor CLTA-4-activated portraits and immune-infiltrating cell populations.